JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2017, Vol. 55 ›› Issue (2): 84-91.doi: 10.6040/j.issn.1671-7554.0.2016.446

Previous Articles     Next Articles

Expression of EZH2 in Chinese Ewing sarcoma patients and its relationship with clinicopathological parameters and prognosis

ZHANG Xiying1, ZHAI Chunyan1, LI Jingsong1,2, HAN Bo1,2   

  1. 1. Department of Pathology, Medical School of Shandong University, Jinan 250012, Shandong, China;
    2. Department of Pathology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Received:2016-04-21 Online:2017-02-10 Published:2017-02-10

PDF (PC)

299

Abstract: Objective To explore the expression of enhancer of zeste homolog 2(EZH2)in Chinese Ewing sarcoma(EWS)patients, and to analyze its correlation with the clinicopathological parameters and prognosis. Methods Tissues from 67 cases of Ewing sarcoma/primitive neuroectodermal tumor(EWS/PNET)and other small round cell malignant tumors were collected and microarrayed. Gene rearrangement in EWS region 1(EWSR1)was evaluated using fluorescence in situ hybridization(FISH). The expressions of EZH2, P53 and Ki-67 were determined using immunohistochemical method. Survival analysis was performed with Kaplan-Meier and Cox method. Results A total of 44 cases were confirmed EWS. EZH2 expression was closely related to lung metastasis(P=0.023)and prognosis(P=0.004)in EWS tissues, and positively correlated to the expression of Ki-67(R=0.406, P=0.006). There was significant correlation between poor prognosis and high expression of EZH2(P=0.06)and high proliferation index of Ki-67(P=0.023). Cox multivariate analysis revealed that there was no significant correlation between P53 expression and overall survival(P>0.05); EZH2 and Ki-67 were independent risk factors for overall survival(HR=3.467, 95%CI=1.138-10.563, P=0.029; HR=2.140, 95%CI=0.439-10.423, P=0.046). In addition, a subset of EWS patients with overexpression of both EZH2 and Ki-67 had the shortest survival time (P=0.012). Conclusion EZH2 and 山 东 大 学 学 报 (医 学 版)55卷2期 -张希英,等.中国尤文肉瘤患者EZH2蛋白表达与临床病理学参数及预后的关系 \=-Ki-67 are independent prognostic factors in Chinese EWS patients. A combined detection of EZH2 and Ki-67 can help to identify the subset with extremely poor prognosis. EZH2 may serve as a novel prognostic marker of Ewing sarcoma.

Key words: Ki-67, Ewing sarcoma, Immunohistochemistry, Prognosis, Enhancer of zeste homolog 2, Clinicopathology

CLC Number: 

  • R574
[1] Surdez D, Benetkiewicz M, Perrin V, et al. Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-β abolishes ewing sarcoma growth[J]. Cancer Res, 2012, 72(17): 4494-4503.
[2] Borinstein SC, Beeler N, Block JJ, et al. A decade in banking ewing sarcoma: a report from the Childrens oncology group[J]. Front Oncol, 2013, 3: 57. doi:10.3389/fonc.2013.00057.
[3] Paulussen M, Bielack S, Jurgens H, et al. Ewing's sarcoma of the bone: ESMO clinical recommendations for diagnosis, treatment and follow-up[J]. Ann Oncol, 2009, 20(Suppl 4): 140-142.
[4] Lu C, Han HD, Mangala LS, et al. Regulation of tumor angiogenesis by EZH2[J]. Cancer Cell, 2010, 18(2): 185-197.
[5] Yoo KH, Hennighausen L. EZH2 methyltransferase and H3K27 methylation in breast cancer[J]. Int J Biol Sci, 2012, 8(1): 59-65.
[6] Tang SH, Huang HS, Wu HU, et al. Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo[J]. Oncotarget, 2014, 5(21): 10342-10355.
[7] Rhodes DR, Sanda MG, Otte AP, et al. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer[J]. J Natl Cancer Inst, 2003, 95(9): 661-668.
[8] Crea F, Hurt EM, Farrar WL. Clinical significance of Polycomb gene expression in brain tumors[J]. Mol cancer, 2010, 9: 265. doi: 10.1186/1476-4598-9-265.
[9] Benard A, Goossens-Beumer IJ, Van Hoesel AQ, et al. Prognostic value of polycomb proteins EZH2, BMI1 and SUZ12 and histone modification H3K27me3 in colorectal cancer[J]. PLoS One, 2014, 9(9): 108265. doi: 10.1371/journal.pone.0108265.
[10] Chen DL, Zhang DS, Lu YX, et al. microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer[J]. Oncotarget, 2015, 6(13): 10868-10879.
[11] Liu H, Liu Y, Liu W, et al. EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma[J]. Nat Commun, 2015, 6:8494. doi: 10.1038/ncomms 9494.
[12] 刘宝岳, 杨郁, 杜娟, 等. EWS易等位分离探针荧光原位杂交和免疫组织化学抗体(FLI-1和CD99)在尤文肉瘤/原始神经外胚层肿瘤诊断中的价值[J]. 北京大学学报(医学版), 2008, 40(4): 358-362. LIU Baoyue, YANG Yu, DU Juan, et al. Application of the in situ hybridization with EWS dual-color break-apart fluorescence probe and anti-CD99 and anti-FIL-1 antibodies in the diagnosis of Ewing sarcoma/primitive neuroectodermal tumor[J]. Journal of Peking University(Health Sciences), 2008, 40(4): 358-362.
[13] Lin YW, Ren LL, Xiong H, et al. Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer[J]. J Pathol, 2013, 230(3): 277-290.
[14] Zhu Q, Zhang L, Li X, et al. Higher EZH2 expression is associated with extramedullary infiltration in acute myeloid leukemia[J]. Tumour Biol, 2016, 37(8): 11409-11420.
[15] 董玉兰, 杨向红, 高英贤, 等. Ki-67及p53蛋白在口腔鳞状上皮肿瘤中的表达及意义[J]. 中国医科大学学报, 2002, 31(2): 16-17. DONG Yulan, YANG Xianghong, GAO Yingxian, et al. Expression of Ki-67 and p53 in oral squamous epithelial tumor and its significance[J]. J Chin Med Univ, 2002, 31(2): 16-17.
[16] Lu N, Lin T, Wang L, et al. Association of SOX4 regulated by tumor suppressor miR-30a with poor prognosis in low-grade chondrosarcoma[J]. Tumour Biol, 2015, 36(5): 3843-3852.
[17] Tirode F, Laud-Duval K, Prieur A, et al. Mesenchymal stem cell features of Ewing tumors[J]. Cancer Cell, 2007, 11(5): 421-429.
[18] Von Levetzow C, Jiang X, Gwye Y, et al. Modeling initiation of Ewing sarcoma in human neural crest cells[J]. PLoS One, 2011, 6(4): 19305. doi: 10.1371/journal. pone.0019305.
[19] Selvanathan SP, Graham GT, Erkizan HV, et al. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing[J]. PNAS, 2015, 112(11): 1307-1316.
[20] Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life[J]. Nature, 2011, 469(7330): 343-349.
[21] Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex[J]. Mol Cell, 2004, 15(1): 57-67.
[22] Montgomery ND, Yee D, Chen A, et al. The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation[J]. Curr Biol, 2005, 15(10): 942-947.
[23] Kim KH, Roberts CW. Targeting EZH2 in cancer[J]. Nat Med, 2016, 22(2): 128-134.
[24] Richter GH, Plehm S, Fasan A, et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation[J]. Proc Natl Sci U S A, 2009, 106(13): 5324-5329.
[25] Staege MS, Hutter C, Neumann I, et al. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets[J]. Cancer Res, 2004, 64(22): 8213-8221.
[26] Riggi N, Suva ML, Suva D, et al. EWS-FLI-1 expression triggers a Ewings sarcoma initiation program in primary human mesenchymal stem cells[J]. Cancer Res, 2008, 68(7): 2176-2185.
[27] Bracken AP, Pasini D, Capra M, et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer[J]. EMBO J, 2003, 22(20): 5323-5335.
[28] Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67[J]. J Immunol, 1984, 133(4): 1710-1715.
[29] Lopez-Guerrero JA, Machado I, Scotlandi K, et al. Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewings sarcoma family of tumors[J]. Int J Cancer, 2011, 128(5): 1139-1150.
[30] Matsukawa Y, Semba S, Kato H, et al. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer[J]. Cancer Sci, 2006, 97(6): 484-491.
[31] Huqun, Ishikawa R, Zhang J, et al. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer[J]. Cancer, 2012, 118(6): 1599-1606.
[1] LI Yinglin, SONG Daoqing, XU Zhonghua. Identification of FKBP11 expression in clear cell renal cell carcinoma using bioinformatics analysis [J]. Journal of Shandong University (Health Sciences), 2020, 1(9): 45-51.
[2] SHI Shuang, LI Juan, MI Qi, WANG Yunshan, DU Lutao, WANG Chuanxin. Construction and application of a miRNAs prognostic risk assessment model of gastric cancer [J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 47-52.
[3] LI Xingkai, LIU Zhanye, JIANG Yunfeng, LI Jun. Clinicopathological factors and prognosis between primary central and peripheral lung squamous cell carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 73-78.
[4] NIE Siyue, WANG Zhen, SUN Jingyu, LIU Jie, LI Juan, WEI Xiaojuan, LU Chunxiao, L(¨overU)Xingyan, WANG Shuyun, SUN Yuping. Expression and clinical significance of angiopoietin-like protein 5 in human gastric cancer tissues [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(8): 61-65.
[5] ZONG Shuai, XIAO Dongjie, LIU Hua, JIA Yanfei, MA Xiaoli, LI Huanjie, LI Ping, ZHENG Yan, WANG Yunshan. Expression of CSN5 and its correlation with the prognosis of gastric carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(7): 12-16.
[6] SUN Qijing, CHEN Fangfang, LI Chunxiao, ZHANG Caiqing. Clinical value of PNI and HGB in evaluating the prognosis of the middle to late stage non-small cell lung cancer patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(4): 55-59.
[7] WANG Yongqiang, ZHANG Weiquan, SUN Qifeng, DONG Xiaopeng, PENG Chuanliang, ZHANG Yuan, ZHAO Xiaogang. Expression and significance of CK14 in non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(3): 83-87.
[8] LIN Jiaxiang, GUO Zijia, SU Peng, WANG Xiao, GUO Yaxin, WU Xiaojuan, XIANG Lei, ZHOU Zhiqiang, WANG Yan, CUI Xiujie, PAN Aifeng, GUO Chenghao. The role of CIP2A in the transformation of breast ductal epithelium and prognosis of invasive breast cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(3): 100-106.
[9] ZHOU Lanlan, PAN Xueyi, GUO Yu. Clinical characteristics and prognosis of 48 patients with mixed phenotype acute leukemia [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(2): 79-83.
[10] LIU Huiling, WANG Xingwen, FENG Shaobin, FENG Hong, HAN Junqing. Association between high expression of scavenger receptor class B type I and the prognosis of colon cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(10): 84-89.
[11] LI Xiaoning, CUI Lianqun. Treatment timing of non-infarct-related artery in patients with multi-vessel disease and acute myocardial infarction [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(8): 50-54.
[12] WANG Wen, LIU Yao, LONG Fei, MA Weixia, SU Lili. Correlation between lymphocyte-to-monocyte ratio in peripheral blood and prognosis of malignant pleural mesothelioma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(8): 72-77.
[13] LIU Tong, ZHANG Xin, WANG Chuanxin. Significance of IRX5 mRNA in the diagnosis and prognosis of colorectal cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(7): 69-74.
[14] MA Lin, ZHANG Dong, TANG Lei, YE Siyuan, YAN Chuanzhu, CAO Lili. Prognostic hematological biomarkers of amyotrophic lateral sclerosis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(4): 46-50.
[15] XU Zhihong, WU Xiaohua, YAO Tiezhu, WANG Xiaoxiang, DUAN Xiaoyang, SHI Jian. Relationship between mir-99a expression and prognosis of epithelial ovarian cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(3): 77-80.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd